4-硝基-N-(2,2,2-三氟乙基)苯甲酰胺 在
钯乙醇 作用下,
以
乙醇 为溶剂,
反应 16.0h,
以to give the title compound as a white solid (290 mg)的产率得到4-amino-N-(2,2,2-trifluoroethyl)benzamide
[EN] COMPOUNDS FOR USE IN INHIBITING HIV CAPSID ASSEMBLY<br/>[FR] COMPOSÉS À UTILISER POUR INHIBER L'ASSEMBLAGE DE CAPSIDE DU VIH
申请人:RUPRECHT KARLS UNIVERSITÄT HEIDELBERG
公开号:WO2014128213A1
公开(公告)日:2014-08-28
The present invention relates a compound or a pharmaceutically acceptable salt or solvate thereof for use in inhibiting HIV capsid assembly, wherein the compound is a pyrimidine being at least substituted in two positions, preferably in 2 and 4 position or in 4 and 6 position, more preferably in 2 and 4 position.
Discovery of Novel Isoxazoline Compounds that Incorporate a <i>para</i>-Diamide Moiety as Potential Insecticidal Agents against Fall Armyworm (<i>Spodoptera frugiperda</i>)
作者:Biaobiao Jiang、Fangyi Li、Di Feng、Wenchao Wei、Yuqin Luo、Siqi He、Yawen Dong、Deyu Hu
DOI:10.1021/acs.jafc.3c00351
日期:——
Spodopterafrugiperda is a major migratory agricultural pest, which seriously impedes agricultural production around the world. To discover potent compoundsagainst S. frugiperda, a number of novelisoxazoline derivatives were designed and synthesized and created on account of the identified lead compound F32 (4-(5-(3,5-dichlorophenyl)-5-(trifluoromethyl)-4,5-dihydroisoxazol-3-yl)-2-methyl-N-(3-pr
Compounds for use in inhibiting HIV capsid assembly
申请人:Ruprecht-Karls-Universität Heidelberg
公开号:EP2769722A1
公开(公告)日:2014-08-27
The present invention relates a compound or a pharmaceutically acceptable salt or solvate thereof for use in inhibiting HIV capsid assembly, wherein the compound is a pyrimidine being at least substituted in two positions, preferably in 2 and 4 position or in 4 and 6 position, more preferably in 2 and 4 position.
METHOD FOR PREPARING PROPANEDINITRILE OXIME ETHER COMPOUND AND INTERMEDIATE COMPOUND
申请人:Shenyang Sinochem Agrochemicals R&D Co., Ltd.
公开号:EP3822253A1
公开(公告)日:2021-05-19
Provided are a method of preparing a malononitrile oxime ether compound and an intermediate compound. The malononitrile oxime ether compound has a structure as shown in formula (VII), wherein W is selected from aryl or heteroaryl. The preparation method comprises steps: reacting a first raw material with a second raw material in the presence of a first solvent and a catalyst to obtain the intermediate compound, wherein the first raw material has a structure as shown in formula (IV), and the second raw material has a structure as shown in formula (V); and subjecting the intermediate compound as shown in formula (VI), and a dehydrant to a dehydrantion reaction in the presence of a second solvent to obtain the malononitrile oxime ether compound. In the preparation process for the intermediate, a cheaper cyanoacetamide is used as a raw material, the reaction conditions are mild. Moreover, the yield of the intermediate compound is high and the cost of the process is low. Furthermore, the required malononitrile oxime ether compound is obtained only through one-step dehydration reaction. Using the preparation method, is advantageous for improving the yield of malononitrile oxime ethers and reducing the cost of the process.
本发明提供了一种丙二腈肟醚化合物和一种中间体化合物的制备方法。丙二腈肟醚化合物的结构如式(VII)所示,其中 W 选自芳基或杂芳基。该制备方法包括以下步骤:在第一溶剂和催化剂存在下,使第一原料与第二原料反应,得到中间体化合物,其中第一原料具有如式(IV)所示的结构,第二原料具有如式(V)所示的结构;以及在第二溶剂存在下,使如式(VI)所示的中间体化合物和脱水剂进行脱水反应,得到丙二腈肟醚化合物。在该中间体的制备过程中,使用了较为廉价的氰乙酰胺作为原料,反应条件温和。此外,中间体化合物的收率高,工艺成本低。此外,只需通过一步脱水反应就能得到所需的丙二腈肟醚化合物。该制备方法有利于提高丙二腈肟醚的产率,降低工艺成本。
[EN] PYRROLOPYRIMIDINE DERIVATIVES AS SYK INHIBITORS<br/>[FR] DÉRIVÉS DE LA PYRROLOPYRIMIDINE INHIBITEURS DE LA Syk
申请人:GLAXO GROUP LTD
公开号:WO2007042299A1
公开(公告)日:2007-04-19
[EN] Pyrrolopyrimidine derivatives of formula (I) are inhibitors of Spleen Tyrosine kinase (Syk) and therefore of potential therapeutic benefit in the treatment of diseases and conditions associated with inappropriate Syk activity, in particular in the treatment of inflammatory and allergic diseases. [FR] La présente invention concerne des dérivés de la pyrrolopyrimidine de formule (I) qui ont une activité d'inhibiteurs de la tyrosine-kinase de la rate (Syk) et qui présentent donc des avantages potentiels dans le traitement de maladies et d'états associés à une activité Syk inappropriée, en particulier des maladies inflammatoires et allergiques.